Last reviewed · How we verify
Flu-ATG
Flu-ATG is an anti-thymocyte globulin derived from immunized rabbits that depletes T lymphocytes to suppress immune-mediated rejection and autoimmune responses.
Flu-ATG is an anti-thymocyte globulin derived from immunized rabbits that depletes T lymphocytes to suppress immune-mediated rejection and autoimmune responses. Used for Aplastic anemia, Acute graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation.
At a glance
| Generic name | Flu-ATG |
|---|---|
| Also known as | Fludarabine, Thymoglobulin |
| Sponsor | Cooperative Study Group A for Hematology |
| Drug class | Polyclonal antithymocyte globulin (ATG) |
| Target | T lymphocytes (CD2, CD3, CD4, CD8, and other T-cell surface antigens) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Hematology |
| Phase | Phase 3 |
Mechanism of action
ATG (anti-thymocyte globulin) works by binding to and eliminating T cells, which are central mediators of immune rejection and autoimmune disease. The polyclonal antibody preparation targets multiple epitopes on T-cell surfaces, leading to complement-dependent and antibody-dependent cellular cytotoxicity. This profound T-cell depletion creates an immunosuppressive state useful in transplantation and severe autoimmune conditions.
Approved indications
- Aplastic anemia
- Acute graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation
Common side effects
- Cytokine release syndrome
- Infection (bacterial, viral, fungal)
- Thrombocytopenia
- Leukopenia
- Fever
- Serum sickness
Key clinical trials
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (PHASE2)
- Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia (PHASE2)
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies (PHASE2)
- Haploidentical HCT for Severe Aplastic Anemia (PHASE2)
- Haplo-HSCT for Myelofibrosis (NA)
- Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT. (NA)
- A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flu-ATG CI brief — competitive landscape report
- Flu-ATG updates RSS · CI watch RSS
- Cooperative Study Group A for Hematology portfolio CI